Trade Biogen Inc. - BIIB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 119.3 |
| Open | 117.23 |
| 1-Year Change | -41.96% |
| Day's Range | 117.23 - 119.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 118.62 | -0.18 | -0.15% | 118.80 | 119.49 | 117.01 |
| Apr 24, 2025 | 119.30 | 0.35 | 0.29% | 118.95 | 119.93 | 117.00 |
| Apr 23, 2025 | 118.02 | -1.71 | -1.43% | 119.73 | 121.57 | 116.85 |
| Apr 22, 2025 | 118.70 | 1.75 | 1.50% | 116.95 | 119.43 | 116.21 |
| Apr 21, 2025 | 116.28 | -0.42 | -0.36% | 116.70 | 118.37 | 115.12 |
| Apr 17, 2025 | 118.44 | 3.58 | 3.12% | 114.86 | 118.56 | 114.14 |
| Apr 16, 2025 | 114.84 | -2.09 | -1.79% | 116.93 | 117.77 | 114.73 |
| Apr 15, 2025 | 116.82 | -1.51 | -1.28% | 118.33 | 119.54 | 116.40 |
| Apr 14, 2025 | 118.69 | 2.54 | 2.19% | 116.15 | 119.81 | 114.89 |
| Apr 11, 2025 | 114.69 | 0.74 | 0.65% | 113.95 | 116.04 | 111.51 |
| Apr 10, 2025 | 113.32 | -3.66 | -3.13% | 116.98 | 118.32 | 110.00 |
| Apr 9, 2025 | 119.80 | 9.58 | 8.69% | 110.22 | 120.87 | 109.98 |
| Apr 8, 2025 | 113.84 | -5.61 | -4.70% | 119.45 | 120.53 | 112.78 |
| Apr 7, 2025 | 119.15 | -2.25 | -1.85% | 121.40 | 123.24 | 116.99 |
| Apr 4, 2025 | 122.61 | -5.92 | -4.61% | 128.53 | 129.45 | 122.06 |
| Apr 3, 2025 | 130.28 | -0.97 | -0.74% | 131.25 | 132.87 | 129.89 |
| Apr 2, 2025 | 131.10 | -0.88 | -0.67% | 131.98 | 133.50 | 128.48 |
| Apr 1, 2025 | 131.86 | -4.57 | -3.35% | 136.43 | 136.90 | 131.19 |
| Mar 31, 2025 | 136.74 | -0.42 | -0.31% | 137.16 | 137.34 | 134.52 |
| Mar 28, 2025 | 137.90 | -2.35 | -1.68% | 140.25 | 140.90 | 137.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Biogen Company profile
Biogen Inc. (BIIB) is a biotechnology company in the field of neurological and neurodegenerative diseases.
Established in 1978 and headquartered in Cambridge, Massachusetts, Biogen has devoted its scientific research to defeating neurological diseases, like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
With the aid of some of the world’s leading neuroscientists and neurologists, Biogen has sought treatments against common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP).
The use of advanced technologies and engineering skills has enabled Biogen to bring effective medicines to the market. The company’s products include SPINRAZA for the treatment of SMA; TECFIDERA, AVONEX, FAMPYRA, VUMERITY and TYSABRI for multiple sclerosis; ADUHELM for Alzheimer’s disease; and FUMADERM for the treatment of severe plaque psoriasis.
Biogen has made an agreement with Genentech, a member of the Roche Group for business and financial rights, with respect to RITUXAN, GAZYVA and OCREVUS. It’s constantly looking at ways to improve its research and development to compete against other biotech giants like Pfizer Inc (PFE), Johnson & Johnson (JNJ) and Amgen (AMGN).
Biogen went public in September 1991. It trades on the Nasqaq under the ticker ‘BIIB’.
| Industry: | Biopharmaceuticals |
225 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com